UBS Group
SNDX icon

UBS Group’s Syndax Pharmaceuticals SNDX Stock Holding History

UBS Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-72,300
Closed -$1.52M – 11116
2025
Q4 		$1.52M Hold
72,300
– – ﹤0.01% 5206
2025
Q3 		$1.11M Buy
+72,300
New +$946K ﹤0.01% 5483
2025
Q1 		– Sell
-20,000
Closed -$264K – 10686
2024
Q4 		$264K Buy
+20,000
New +$342K ﹤0.01% 6284
2023
Q4 		– Sell
-60,000
Closed -$871K – 9838
2023
Q3 		$871K Buy
+60,000
New +$1.13M ﹤0.01% 4200
2020
Q1 		– Sell
-5,000
Closed -$44K – 8363
2019
Q4 		$44K Buy
+5,000
New +$36.7K ﹤0.01% 6423

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return